Interferon-alpha intranasal - Marina Biotech

Drug Profile

Interferon-alpha intranasal - Marina Biotech

Alternative Names: Intranasal interferon - alpha

Latest Information Update: 03 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Marina Biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Hepatitis B; Hepatitis C

Most Recent Events

  • 03 Feb 2017 Discontinued - Phase-I for Cancer in USA (Intranasal)
  • 03 Feb 2017 Discontinued - Phase-I for Hepatitis B in USA (Intranasal)
  • 03 Feb 2017 Discontinued - Phase-I for Hepatitis C in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top